Thrombolytics are the standard of care for acute stroke yet are not without risk. Join host, Geoff Wall, with guest, Jake Galdo, as they discuss combination aspirin and clopidogrel versus thrombolytics in mild stroke.
 
The GameChanger
Thrombolytic use in mild stroke is common due to the time factor of administration, but data is mixed. New research has shown DAPT to be non-inferior to TPA.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
 
Reference
Chen H, Cui Y, Zhou Z, et al. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023;329(24):2135–2144. doi:10.1001/jama.2023.7827

https://jamanetwork.com/journals/jama/article-abstract/2806532

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss how the inclusion and exclusion criteria impact the interpretation of the ARIMIS study
2. Describe the potential benefits of DAPT therapy compared to thrombolytic therapy in mild stroke

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-249-H01-P
Initial release date: 7/31/2023
Expiration date: 7/31/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram